Endocrine resistance in breast cancer: Current status and a perspective on the roles of miRNAs (Review)

被引：16

作者：

Zhou, Jichun ^{[1
]}

Teng, Rongyue ^{[1
]}

Wang, Qinchuan ^{[1
]}

Xu, Chenpu ^{[1
]}

Guo, Jufeng ^{[1
]}

Yuan, Chao ^{[1
]}

Shen, Jianguo ^{[1
]}

Hu, Wenxian ^{[1
]}

Wang, Linbo ^{[1
]}

Xie, Shuduo ^{[1
]}

机构：

[1] Zhejiang Univ, Sch Med, Sir Run Run Shaw Hosp, Dept Surg Oncol, Hangzhou 310016, Zhejiang, Peoples R China

来源：

ONCOLOGY LETTERS | 2013年 / 6卷 / 02期

基金：

中国国家自然科学基金;

关键词：

miRNAs; breast cancer; endocrine resistance; ESTROGEN-RECEPTOR-ALPHA; MICRORNA EXPRESSION; POSTMENOPAUSAL WOMEN; GENE-EXPRESSION; TAMOXIFEN RESISTANCE; AROMATASE INHIBITORS; DOWN-REGULATION; TUMOR INVASION; SMALL RNAS; THERAPY;

D O I：

10.3892/ol.2013.1405

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Current endocrine therapies for females with estrogen receptor-positive breast cancer have facilitated substantial improvements in outcomes. The effectiveness of endocrine therapy is limited by either initial de novo resistance or acquired endocrine resistance. Multiple mechanisms responsible for endocrine resistance have been proposed, including deregulation of various components of the estrogen receptor (ER) pathway, alterations in cell cycle and cell survival signaling molecules, and the activation of escape pathways. Dysregulation of miRNA expression has been associated with experimental and clinical endocrine therapy resistance. miRNAs are pivotal to understanding the complex biological mechanism of endocrine resistance, and may serve as novel candidate predictive and prognostic surrogates and therapeutic targets. This review focuses on current progress concerning the roles of miRNAs in endocrine resistance, and discusses the challenges and opportunities for implementing miRNA-based assays and treatment for patients with endocrine-resistant breast cancer.

引用

页码：295 / 305

页数：11

共 50 条

[1] Roles for miRNAs in endocrine resistance in breast cancer
Muluhngwi, Penn
Klinge, Carolyn M.
[J]. ENDOCRINE-RELATED CANCER, 2015, 22 (05) : R279 - R300
[2] miRNAs modulating endocrine resistance in breast cancer
Krell, Jonathan
Frampton, Adam E.
Cascorbi, Ingolf
Werk, Anneke
Stebbing, Justin
[J]. PHARMACOGENOMICS, 2012, 13 (06) : 645 - 646
[3] Identification of miRNAs as biomarkers for acquired endocrine resistance in breast cancer
Muluhngwi, Penn
Klinge, Carolyn M.
[J]. MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2017, 456 (0C) : 76 - 86
[4] Current status of endocrine therapy for breast cancer
Yasuo Miyoshi
Tetsuya Taguchi
Yasuhiro Tamaki
Shinzaburo Noguchi
[J]. Breast Cancer, 2003, 10 (2) : 105 - 111
[5] Emerging roles of exosomal miRNAs in breast cancer drug resistance
Najminejad, Hamid
Kalantar, Seyed Mehdi
Abdollahpour-Alitappeh, Meghdad
Karimi, Mohammad Hossein
Seifalian, Alexander M.
Gholipourmalekabadi, Mazaher
Sheikhha, Mohammad Hasan
[J]. IUBMB LIFE, 2019, 71 (11) : 1672 - 1684
[6] Molecular perspective on targeted therapy in breast cancer: a review of current status
Demir Cetinkaya, Busra
Biray Avci, Cigir
[J]. MEDICAL ONCOLOGY, 2022, 39 (10)
[7] Molecular perspective on targeted therapy in breast cancer: a review of current status
Busra Demir Cetinkaya
Cigir Biray Avci
[J]. Medical Oncology, 39
[8] Endocrine therapy resistance in breast cancer: current status, possible mechanisms and overcoming strategies
Fan, Weimin
Chang, Jinjia
Fu, Peifeng
[J]. FUTURE MEDICINAL CHEMISTRY, 2015, 7 (12) : 1511 - 1519
[9] Current status of adjuvant endocrine therapy for breast cancer
Ingle, JN
[J]. CLINICAL CANCER RESEARCH, 2001, 7 (12) : 4392S - 4396S
[10] Current status of endocrine therapy for advanced breast cancer
Bland, KI
[J]. ANNALS OF SURGICAL ONCOLOGY, 1999, 6 (08) : 4S - 7S

← 1 2 3 4 5 →